Tolerability of antihypertensive drugs in a community-based setting

Clinical Therapeutics

Volumn 23, Issue 5, 2001, Pages 715-726

  Grégoire, Jean Pierre ^a,d   Moisan, Jocelyne ^a   Guibert, Rémi ^b   Ciampi, Antonio ^c   Milot, Alain ^a   Côté, Isabelle ^a   Gaudet, Michel ^a  

^a UNIVERSITÉ LAVAL   (Canada)

^b MONASH UNIVERSITY   (Australia)

^c MCGILL UNIVERSITY   (Canada)

^d LAVAL UNIVERSITY   (Canada)

Author keywords

Clinical practice; Drug treatment; Hypertension; Side effects

Indexed keywords

ANGIOTENSIN II ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; COUGHING; DRUG CHOICE; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; VERTIGO; XEROSTOMIA;

EID: 0034996060     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(01)80021-7     Document Type: Article

References (27)

1. 1. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765-774.
2. 2. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA. 1997;277:739-745.
3. 3. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995; 25:305-313.
4. 4. Burt VL, Cutler JA, Higgins M, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. Hypertension. 1995;26:60-69.
5. 5. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda, Md: National Heart, Lung and Blood Institute; 1997.
6. 6. Rizzo JA, Simons WR. Variations in compliance among hypertensive patients by drug class: Implications for health care costs. Clin Ther. 1997;19:1446-1467.
7. 7. Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol. 1995;75:793-795.
8. 8. Gradman AH, Arcuri KE, Goldberg AI, et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension. 1995; 25:1345-1350.
9. 9. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997;349:747-752.
10. 10. Kramer MS. Clinical Epidemiology and Biostatistics. A Primer for Clinical Investigators and Decision-makers, Berlin: Springer-Verlag; 1988:86-87.
11. 11. Caro JJ, Speckman JL. Existing treatment strategies: Does noncompliance make a difference? J Hypertens Suppl. 1998;16: S31-S34.
12. 12. Jones JK, Gorkin L, Lian JF, et al. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: A study of a United Kingdom population. Br Med J, 1995;311:293-295.
13. 13. Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther. 1998;20:671-681.
14. 14. Caro JJ, Salas M, Speckman JL, et al. Persistence with treatment for hypertension in actual practice. Can Med Assoc J. 1999, 160:31-37.
15. 15. Johnston CI. Angiotensin receptor antagonists: Focus on losartan. Lancet. 1995; 346:1403-1407.
16. 16. Morisky DE, Green LW, Levine DM, Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24:67-74.
17. 17. Nunnally JC. Psychometric Theory. 2nd ed. New York: McGraw-Hill Book Company; 1978:225-255.
18. 18. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York: John Wiley & Sons; 1989:25-37.
19. 19. Belsley D, Kuh E, Welsch R, Regression Diagnostics: Identifying Influential Data and Sources of Collinearity. New York: Wiley; 1980:98-115.
20. 20. SAS Institute Inc. SAS/STAT User's Guide, Version 6. 4th ed. Cary, NC: SAS Institute Inc; 1989.
21. 21. Collet JP, Boivin JF, Spitzer WO. Bias and confounding in pharmacoepidemiology. In: Strom BL, ed. Pharmacoepidemiology. 2nd ed. Chichester: John Wiley & Sons; 1994:609-627.
22. 22. Curb JD, Borhani NO, Blaszkowski TP, et al. Patient-perceived side effects to antihypertensive drugs. Am J Prev Med. 1985; 1:36-40.
23. 23. Wallin J, Sjovall J. Detection of adverse drug reactions in a clinical trial using two types of questioning. Clin Ther. 1981;3: 450-452.
24. 24. Goldszer RC, Lilly LS, Solomon HS. Prevalence of cough during angiotensin-converting enzyme inhibitor therapy. Am J Med. 1988;85:887.
25. 25. Lefebvre J, Poirier L, Lacourcière Y. Prospective trial on captopril-related cough. Ann Pharmacother. 1992;26:161-164.
26. 26. Yeo WW, Ramsey LE, Persistent dry cough with enalapril: Incidence depends on method used. J Hum Hypertens. 1990; 4:517-520.
27. 27. Luque CA, Vasquez Ortiz M. Treatment of ACE inhibitor-induced cough. Pharmacotherapy. 1999;19:804-810.